Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013

Yes
Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that the first phase I study with ADC-1013, a
Läs Mer

Alligator Bioscience Annual Report for 2016 published

Yes
Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) today announces that that the Swedish version of Annual Report for
Läs Mer

Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)

Yes
The shareholders of Alligator Bioscience AB, Reg. No 556597-8201, are hereby invited to attend the annual shareholders’ meeting to be
Läs Mer

Alligator Bioscience AB Full Year 2016 Report

Yes
Summary During the quarter were the company’s shares listed for trading on Nasdaq Stockholm Mid Cap. In connection with this
Läs Mer

Conference call for investors, analysts and the media on Friday, February 17 in connection with the company’s Full Year Report

No
Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) announced today that it will host a teleconference in connection to
Läs Mer

Change in number of shares and votes in Alligator Bioscience AB (publ)

Yes
During December, the number of shares and votes in Alligator Bioscience AB (publ) has increased due to that 700,000 warrants
Läs Mer

Change in number of shares and votes in Alligator Bioscience AB (publ)

No
During December, the number of shares and votes in Alligator Bioscience AB (publ) has increased due to that 100,000 warrants
Läs Mer

Exercise of over-allotment option and notice of stabilisation in Alligator Bioscience

No
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY
Läs Mer

Notice of stabilisation measures

No
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY
Läs Mer

News archives